Press releases

Stockholm – December 5, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program is now available below and on the company website: www.oncopeptides.com / Investors & media / Calendar. The event will be webcasted

Stockholm – December 3, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®) from the ongoing HORIZON trial at the 60th ASH meeting in San Diego, California, USA

Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentation of the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA

Stockholm — 30 November, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs

Stockholm - 5 November 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the notice for an Extraordinary General Meeting in which the Nomination Committee is proposing one new candidate for the Board of Directors. Over the last few years, Oncopeptides has taken its lead compound closer to market and is currently conducting pivotal trials with melflufen (Ygalo®). The company continues to prepare for stand-alone commercialisation in the US and Europe. As part of these activities, the Nomination Committee has worked to strengthen the profile of the Board of Directors with regard to commercialisation in general and the US market in particular

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Wednesday 5 December 2018 at 3:00 p.m. Coffee will be served starting at 2:00 p.m., at which time the registration for attendees will commence

Stockholm – 1 November 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December 1st-4th, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR). The ANCHOR and HORIZON abstracts can be found on the company webpage. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th. Further data supporting melflufen’s activity has been generated since the abstract data cut and will be presented at ASH

Stockholm —October 31, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs

“Broad based progress”

Stockholm – October 25, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York. Speakers will include Jakob Lindberg, Chief Executive Officer, other members of management and Professor Paul G Richardson, Dana-Farber Cancer Institute, Clinical Program Leader & Director of Clinical Research, Jerome Lipper Multiple Myeloma Center. The event will also be webcasted. A detailed program will be published in beginning of December